Država: Južnoafrička Republika
Jezik: engleski
Izvor: South African Health Products Regulatory Authority (SAHPRA)
Smith_kb
AUGMENTIN® 375 tablets AUGMENTIN® 625 tablets AUGMENTIN® BD tablets 10714.062.1 SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): AUGMENTIN ® 375 tablets AUGMENTIN ® 625 tablets AUGMENTIN ® BD tablets COMPOSITION: AUGMENTIN 375: White/off-white, oval, film coated tablets containing amoxycillin trihydrate equivalent to 250 mg amoxycillin and potassium clavulanate equivalent to 125 mg clavulanic acid . AUGMENTIN 625: White/off-white, oval, film coated tablets containing amoxycillin trihydrate equivalent to 500 mg amoxycillin and potassium clavulanate equivalent to 125 mg clavulanic acid. AUGMENTIN BD White/off-white, capsule-shaped, film coated tablets containing amoxycillin trihydrate equivalent to 875 mg amoxycillin and potassium clavulanate equivalent to 125 mg clavulanic acid. PHARMACOLOGICAL CLASSIFICATION: A.20.1.2 Penicillins PHARMACOLOGICAL ACTION: (a) Bacteriology: (i) Spectrum: AUGMENTIN is the group name for formulations containing 2, 4 and 7 parts of a broad spectrum penicillin, amoxycillin and 1 part of potassium clavulanate. Potassium clavulanate has been shown in vitro to be an irreversible inhibitor of beta-lactamases produced by: Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Haemophilus influenzae, Neisseria gonorrhoea and Bacteroides fragilis. Potassium clavulanate does not inactivate the chromosomally mediated (Sykes Type 1 Cephalosporinase) beta-lactamases produced by Acinetobacter species, Citrobacter species, Enterobacter, Indole positive Proteus, Providencia species and Serratia marcescens. In vitro the formulation showed synergism against amoxycillin- resistant organisms, with no evidence of antagonism and the activity was not reduced in the presence of serum. (In vitro activity does not necessar Pročitajte cijeli dokument